NCT00715039 - Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder | Biotech Hunter

Enrollment

169

Participants

Timeline

Start Date

October 31, 2003

Study Completion Date

May 31, 2004

Conditions

Anxiety Disorders

Interventions

DRUG

lorazepam

1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days

DRUG

placebo

placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine

DRUG

paroxetine

20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind

Trial Locations (15)

30060

Pfizer Investigational Site, Marietta

30328

Pfizer Investigational Site, Atlanta

32707

Pfizer Investigational Site, Casselberry

32806

Pfizer Investigational Site, Orlando

66209

Pfizer Investigational Site, Overland Park

66211

Pfizer Investigational Site, Overland Park

87102

Pfizer Investigational Site, Albuquerque

87104

Pfizer Investigational Site, Albuquerque

91206

Pfizer Investigational Site, Glendale

91403

Pfizer Investigational Site, Sherman Oaks

91406

Pfizer Investigational Site, Northridge

Pfizer Investigational Site, Van Nuys

92105

Pfizer Investigational Site, San Diego

92868

Pfizer Investigational Site, Orange

45267-0559

Pfizer Investigational Site, Cincinnati